日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Polypharmacology of S-1117, an Fc-fused IgG-selective degrading enzyme, for chronic treatment of autoantibody-mediated diseases

S-1117(一种Fc融合的IgG选择性降解酶)的多药理学作用,用于慢性治疗自身抗体介导的疾病

Sanmarco, Liliana M; Pellerin, Alex; Green, Tobias; Plasencia, Agustin; Anderson, Jordan M; Le, Nam; Newton, Andita; Chen, Jiyun; Ramello, Maria Cecilia; Peckner, Ryan; Manasson, Julia; Xing, Yi; Vital, Heather; Higginson-Scott, Nathan; Sundy, John S; Otipoby, Kevin L; Mascanfroni, Ivan D

Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology

治疗性IgG和IgM特异性蛋白酶可消除驱动重症肌无力病理的乙酰胆碱受体自身抗体。

Bayer, Alexandra C; Sanmarco, Liliana M; Pellerin, Alex; Masi, Gianvito; Plasencia, Agustin; Anderson, Jordan M; Nowak, Richard J; Damato, Valentina; Massacesi, Luca; Pham, Minh C; Khani-Habibabadi, Fatemeh; Vital, Heather; Higginson-Scott, Nathan; Otipoby, Kevin L; Xing, Yi; Mascanfroni, Ivan D; O'Connor, Kevin C

Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.

MK-6194(一种旨在选择性激活调节性 T 细胞的 IL-2 突变体)的安全性、药代动力学和药效学:单次递增剂量和多次递增剂量试验数据

Scheid Johannes F, Cunningham-Bussel Kiki, Kim Nancy, Agarwal Shiuli, Nieddu Garrett, Cote Josee, Lemoine Lieselotte, Decaesteker Tatjana, Mendez Luis, Paul Erina, Love-Gregory Latisha, Contreras Alejandra Virginia, Zhao Xuemei, Franco-Dilone Lucia, Pang Ling, Baltus Gretchen A, Beaumont Maribel, Shah Ketal, Higginson-Scott Nathan, Kis-Toth Katalin, Otipoby Kevin L, Viney Joanne L, Sicard Eric, Rottey Sylvie, Sundy John S, Van Dyck Kristien, Laethem Tine, Larson Patrick, Sutradhar Santosh, Wnek Richard, Bueters Tjerk, Lai Eseng, Stoch S Aubrey, Iwamoto Marian, Robbins Jonathan A

HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2 in Humanized Mice

人源化小鼠中低剂量IL-2的治疗效果并不需要人Treg细胞的HLA限制性

Tyagi, Rajeev K; Jacobse, Justin; Li, Jing; Allaman, Margret M; Otipoby, Kevin L; Sampson, Erik R; Wilson, Keith T; Goettel, Jeremy A

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

CD62L 不是预测接受那他珠单抗治疗的 R-MS 患者 PML 风险的可靠生物标志物

Linda A Lieberman, Wanyong Zeng, Carol Singh, Wenting Wang, Kevin L Otipoby, Christine Loh, Tatiana Plavina, Leonid Gorelik, Richard M Ransohoff, Ellen Cahir-McFarland

Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms

抗 BDCA2 单克隆抗体通过 Fc 依赖性和 Fc 非依赖性机制抑制浆细胞样树突状细胞活化

Alex Pellerin, Karel Otero, Julie M Czerkowicz, Hannah M Kerns, Renée I Shapiro, Ann M Ranger, Kevin L Otipoby, Frederick R Taylor, Thomas O Cameron, Joanne L Viney, Dania Rabah

Unidirectional Cre-mediated genetic inversion in mice using the mutant loxP pair lox66/lox71

利用突变型loxP对lox66/lox71在小鼠中进行单向Cre介导的基因倒位

Oberdoerffer, Philipp; Otipoby, Kevin L; Maruyama, Mitsuo; Rajewsky, Klaus